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INTRODUCTION
Insulin is a small (6 kDa) dual-chain peptide hor-
mone secreted by the pancreatic b cells,1 which is chiefly
responsible for glucose homeostasis in higher organisms.
The physiological action of insulin is mediated by the
insulin receptor (IR), a close homologue of the type-1
insulin-like growth factor receptor (IGF1R), both of
which are constitutively homo-dimeric transmembrane
glycoproteins of the receptor tyrosine kinase (RTK) super-
family.2–5 Each monomer in the receptor homo-dimer is
comprised of two leucine-rich domains (L1 and L2) sepa-
rated by a cysteine-rich (CR) domain and followed by
three fibronectin type-III repeats, F1, F2, and F3, which is
connected via a single transmembrane helix to the intra-
cellular kinase domain.6 Although the molecular details
of insulin binding and receptor activation remain elusive,
partly due to the lack of structure of the hormone-bound
receptor, the crystal structure of apo-IR (IRDb7; PDB
code 2DTG) has provided structural bases for domain or-
ganization in the IR homodimer,8–13 where subunits are
arranged in a ‘‘folded-over inverted V’’ conformation with
each of the two insulin-binding pockets formed by the
(L1–CR–L2) motif of one subunit and the (F1–F2–F3)
motif of the other subunit. A homology model of the
IGF1R ectodomain validated by small-angle X-ray scatter-
ing (SAXS) data displays similar overall architecture.14
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ABSTRACT
Insulin regulates blood glucose levels in higher organisms by binding to and activating insulin receptor (IR), a constitutively
homodimeric glycoprotein of the receptor tyrosine kinase (RTK) superfamily. Therapeutic efforts in treating diabetes have
been significantly impeded by the absence of structural information on the activated form of the insulin/IR complex. Muta-
genesis and photo-crosslinking experiments and structural information on insulin and apo-IR strongly suggest that the dual-
chain insulin molecule, unlike the related single-chain insulin-like growth factors, binds to IR in a very different conforma-
tion than what is displayed in storage forms of the hormone. In particular, hydrophobic residues buried in the core of the
folded insulin molecule engage the receptor. There is also the possibility of plasticity in the receptor structure based on these
data, which may in part be due to rearrangement of the so-called CT-peptide, a tandem hormone-binding element of IR.
These possibilities provide opportunity for large-scale molecular modeling to contribute to our understanding of this system.
Using various atomistic simulation approaches, we have constructed all-atom structural models of hormone/receptor com-
plexes in the presence of CT in its crystallographic position and a thermodynamically favorable displaced position. In the
‘‘displaced-CT’’ complex, many more insulin–receptor contacts suggested by experiments are satisfied, and our simulations
also suggest that R-insulin potentially represents the receptor-bound form of hormone. The results presented in this work
have further implications for the design of receptor-specific agonists/antagonists.
Proteins 2013; 81:1017–1030.
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Furthermore, site-specific mutagenesis, photo cross-
linking, and chimeric receptor studies have provided
detailed information on residues involved in the hor-
mone/receptor interfaces.3–5,8,11,15–38 Specifically, insu-
lin and IR interact via ‘‘site-1’’ and ‘‘site-2’’ epitopes
(Supporting Information Table S1): the site-1 residues of
IR reside in the central b-sheets of the L1 domain and in
a structural motif of the F2 domain known as the C-ter-
minal peptide (CT), while site-2 residues of IR belong to
the C-terminal loops of F1 and the N-terminal loops of
F2; and the site-1/2 of insulin have residues both from
the A- and B-chain. All hormone-binding residues of IR
were resolved in the IRDb structure (PDB code 2DTG),
except for those in CT. Importantly, Smith et al.39 have
now unambiguously resolved residues 693–710 of CT
along the L1 surface of IR. The refined IRDb structure
(PDB code 3LOH) shows that the CT-peptide is an a-
helix packed against the chiefly nonpolar surface of the
central b-sheets of the L1 domain (Supporting Informa-
tion Fig. S1). Despite nearly-complete characterization of
the hormone-binding epitopes of IR, it has proven diffi-
cult to reconcile mutagenesis data for following reasons:
(a) known crystal structures of the wild-type hormone
display an inactive storage form,40 where a key receptor-
binding surface of hormone remains hidden; (b) the
exact mechanism of the reorganization of the C-terminus
of the B-chain of insulin that exposes the N-terminal res-
idues of the A-chain41–44 on receptor binding remains
unknown; and (c) a model of the hormone/receptor
complex45 would imply significant structural overlap
between insulin and CT,39 suggesting displacement of
CT by insulin10 with additional likely structural rear-
rangements in the hormone as well as the receptor.
Using the structures of the apo-ectodomains of IR7 and
IGF1R,14 we have previously proposed all-atom structural
models for the ligand/receptor complexes.46,47 These struc-
tural models provide molecular description of many resi-
due-based contacts at the ligand/receptor interfaces, and
delineate asymmetric flexibility mechanisms of receptors
that are consistent with the notion of a ‘‘see-saw’’ model of
negative cooperativity in insulin binding7,48 and a ‘‘har-
monic-oscillator’’ model of receptor activation.49 Nonethe-
less, our insulin/IRDb structural models46 remain limited
due to: (a) the absence of then-unresolved CT-peptide, a
critical structural element50 without which IR has drasti-
cally reduced affinity for insulin,22,29–32 and (b) the ab-
sence of any significant conformational change in the re-
ceptor-bound intact T and R insulin needed to explain
interaction of several insulin residues with L1.
However, the availability of new structural information
on the CT-peptide,39 and a novel conformational sam-
pling algorithm for proteins51 provide a timely opportu-
nity to address following yet unresolved key questions:
(1) Is it possible to accommodate intact T and R insulin
in either of the two binding pockets of IRDb with CT
present in the same location and conformation as observed
in the refined IRDb structure?39 (2) If yes, how thermo-
dynamically costly are conformational changes in insulin
that displace the C-terminus of the B-chain under the
condition that CT remains in its crystallographic position?
We have now addressed these questions by first construct-
ing all-atom structural models of T and R insulin with
IRDb in the presence of CT, and then characterizing the
conformational change in the C-terminus of the B-chain
of each insulin using a judicious combination of tempera-
ture-accelerated molecular dynamics (TAMD)51–53 and
the string method in collective variables (CVs).54 Our
analyses of these structural models argue for a different
mode of insulin binding in which the incoming ligand
displaces the potentially flexible helical CT peptide via its
canonical B-chain helix. More importantly, this ‘‘alterna-
tive’’ mode of insulin binding (where CT is displaced) is
thermodynamically favorable and also helps rationalize
observations on helical insulin mimetic peptides that can
compete with CT for binding to L1,50 and can serve as
high-affinity agonists/antagonists of IR.55,56
METHODS
Molecular dynamics simulations and
Monte-Carlo docking
All docking calculations were carried out using our
previously successful MD-assisted Monte-Carlo (MC)
docking algorithm where independent conformational
sampling of both ligand and receptor is carried out from
solvated and MD-equilibrated solution ensembles of each
protein along with MC translational and rotational trial
moves (see Supporting Information Methods for addi-
tional details).46,47,57 All MD and TAMD simulation
trajectories were generated using NAMDv2.858 and the
CHARMM force-field59 with the CMAP correction.60
VMDv1.961 was used for system creation and protein
rendering (see Supporting Information Methods for sim-
ulation set-up and execution).
RESULTS
T/IRDb and R/IRDb structural models with CT
Using an MD simulation assisted MC docking algo-
rithm,46,47,57 we constructed docked structural models
of T/IRDb and R/IRDb complexes in the presence of a
crystallographically positioned CT peptide. Briefly, we
first incorporated the CT-peptide (from the refined IRDb
structure; PDB code 3LOH) in apo-IR conformations
that allowed binding of intact T and R insulin previ-
ously,46 and performed MC docking using independent
conformational sampling of each ligand from an ensem-
ble of solution conformations generated via MD simula-
tions (see Supporting Information Methods for details on
complex generation). Two final models (one for each in-
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sulin/receptor complex) that display highest degree of
agreement with experimentally known insulin/IR interac-
tions are shown in Figure 1. Overall, each intact insulin
molecule could be docked relatively easily despite the
presence of CT (in the same conformation as observed in
refined IRDb structure; PDB code 3LOH) in the binding
pocket, confirming our earlier speculation.46 Specifically,
these structural models have following salient features at
site-1: (i) the side-chain of ValB12 sits close to Leu36 and
Asp12 (L1) in T/IRDb, while the same side-chain inter-
acts with Leu36 and Gln34 (L1) in R/IRDb; (ii) the side-
chain of TyrB16 lies in close proximity to Phe39 (L1) and
His710 (CT) in both complexes; (iii) GluB13 salt-bridges
to Arg14 (L1) in T/IRDb; however, the same residue salt-
bridges to Lys703 (CT) in R/IRDb; (iv) the side-chain of
HisB10 is in the proximity of Lys703 and Thr704 (CT) in
T/IRDb, but does not contact any residue of CT in R/
IRDb; (v) the side-chains of PheB24, PheB25, and TyrB26
in both models do not directly contact any residue of L1/
CT because the C-terminus of the B-chain (B21–B30; la-
beled C in Fig. 1) lies in a narrow cleft between the L1
and CR domains; (vi) due to the hindrance posed by the
C-terminus of the B-chain of each insulin, no contacts
between the A-chain of either insulin with L1/CT are
observed. At site-2: (i) in T/IRDb, the cluster formed by
the side-chains of SerA12, LeuA13, TyrA14, and GluA17
interacts with Leu552, Arg554, Lys557, and Leu558 (F1),
while LeuB17 and ValB18 interact with Asp483 and Lys484;
(ii) in R/IRDb, the side-chains of SerA12, LeuA13, TyrA14,
and GluA17 interact with Lys484 and Leu552, while LeuB17
and ValB18 interact with Arg554, Lys557, and Leu558 (F1).
Each of these structural models was further equili-
brated for 11 ns via explicit-solvent MD simulations (see
Supporting Information Results for dynamics of the re-
ceptor and bound-ligands during these MD trajectories).
Both insulin molecules remain stably bound along with
CT on this time-scale. However, neither of the insulin
molecules undergoes any significant conformational cha-
nge in their C-terminus of the B-chain (B21–B30) during
MD equilibration, precluding the observation of contacts
between the N-terminal residues of the A-chain with L1/
CT. Previously,46 our relatively longer unbiased simula-
tions also failed to show this well-known41–43,62,63 con-
formational change in the C-terminus of the B-chain of
receptor-bound insulin that mediates specificity of hor-
mone binding to IR,64 likely because the underlying free-
energy barriers are difficult to surmount on reasonable
time-scales. To further understand the flexibility of the C-
terminus of the B-chain of each insulin, we carried out
longer (10 ns) explicit-solvent MD equilibration runs of
Figure 1
Representations of Monte-Carlo (MC) docked and energy-minimized
configurations of (A) T-insulin/IRDb complex, and (B) R-insulin/IRDb
complex in presence of the CT-peptide. Receptor domains are shown
in transparent white cartoons, and the A- and B-chain of each insulin
are in the light-blue and dark-blue cartoons, respectively. The C-termi-
nus of the B-chain of each insulin is labeled C, and the C-terminal
peptide (CT) of IR is labeled and depicted as red cartoon. Known
site-1 and site-2 residues of insulin and IR (zoomed views) are labeled
(only for T/IRDb complex) and shown in color as sticks: green indi-
cates site 1 residues on insulin and IR, while cyan indicates corre-
sponding site 2 residues for both. The labels for the site-1 and site-2
residues of insulin in each ligand/receptor complex are italicized.
Green arrows in the left panels indicate viewing directions for insets a
and b on the right, which highlight residue–residue contacts between
each insulin, CT-peptide, and the L1 domain. The snapshots of resi-
due–residue contacts for each insulin/IRDb complex after MD equili-
bration are shown in the Supporting Information. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.
com.]
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wild-type T and R-insulin. From these runs, we observed
that R-insulin can spontaneously undergo a conforma-
tional change in the C-terminus of its B-chain that
exposes the residues in the N-terminus of the A-chain
(Supporting Information Fig. S15). We note that our MC
trials to dock this ‘‘pre-opened’’ R-insulin with CT in its
crystallographic position (PDB code 3LOH) failed to
achieve a successful docking likely due to steric clashes
between the C-terminus of the B-chain and the domains
of IR. Hence, we resorted to a recently proposed confor-
mational sampling algorithm for proteins by Abrams and
Vanden-Eijnden51 based upon the TAMD equations52,53
to characterize the conformational change in the C-termi-
nus of the B-chain of each receptor-bound insulin in the
T/IRDb and R/IRDb complexes described above.
TAMD simulations of the C-terminus of the
B-chain of receptor-bound insulin molecules
We carried out two (one for each complex) 40-ns
long TAMD simulations of hormone-bound receptor
complexes in which the CT of the receptor was not dis-
placed relative to the 3LOH structure, where enhanced
conformational sampling of the C-terminus of the
B-chain of each insulin was allowed. We chose the Carte-
sian coordinates of centers of mass of spatially contigu-
ous groups of residues as collective variables (CVs).
Particularly, the residues in the C-terminus of the B-
chain (B23–B30) of each insulin were divided into four
subgroups (four groups of two residues each; 12 CVs),
and TAMD was applied to these CVs at a fictitious ther-
mal energy of b1 5 6 kcal/mol (see Supporting Infor-
mation Methods). We show evolution of the root-mean
squared deviation (RMSD) of the C-terminus of the B-
chain residues (B21–B30; Ca) of each insulin, and key
buried surface areas (BSA) during TAMD simulations in
Figure 2(A). Shown in Figure 2(B) are snapshots at vari-
ous time-points highlighting the C-terminus of the B-
chain, the L1/CR domain, CT, and each insulin molecule.
Specifically, we observe the following: (i) the opening of
the C-terminus of the B-chain of each insulin (as indi-
cated by increasing RMSD; ﬃ) results in significant ex-
posure of respective insulin molecules (see decreasing
BSA between the C-terminal residues of the B-chain of
each insulin and rest of the insulin molecules; ﬄ); (ii)
exposure of the hydrophobic core of R-insulin molecule
is commensurate with remarkable (five times) increase
in BSA between the L1 domain and R-insulin (cyan trace;
), while T-insulin fails to achieve increased registry
with the L1 domain (black trace; ); (iii) during confor-
mational change in the C-terminus of the B-chain of
each insulin, CT does not dissociate and maintains on
average similar BSA with L1 as observed in the crystal
structure (PDB code 3LOH) for each insulin (Ð); and
Figure 2
TAMD-generated conformational change in the C-terminus of the B-chain of each insulin. (A) Traces (T, black; R, cyan) of the root-mean squared
deviation (RMSD) and buried surface area (BSA) versus simulation time (ns) are shown for each insulin/IRDb complex. Circled digits indicate the
following: (ﬃ) RMSD of the C-terminus (residue B21–B30) of the B-chain of each insulin. For RMSD computation, the insulin molecules were aligned based upon
the residues of each A- and B-chain (A1–A21 and B1–B20; Ca); (ﬄ) BSA between the C-terminus of the B-chain (residues B21–B30) of the B-chain of each insulin and
rest of the insulin molecules; () BSA between each insulin molecule (except the B-chain residues B21–B30) and the L1 domain; and (Ð) BSA between CT and the L1
domain. Horizontal lines indicate the values measured in the IRDb crystal structure (PDB code 3LOH) except the dotted horizontal lines that are arbitrarily
drawn for guidance. (B) Conformational change in the C-terminus of the B-chain of each insulin is highlighted. Representative snapshots of each
insulin (transparent blue), CT (transparent red), and the L1 and CR domains of IRDb (transparent white) are shown at various time-points of re-
spective TAMD simulations. The residues FB24, FB25, and YB26 are shown in sticks and labeled in the first snapshot for each insulin/IRDb complex.
Initial positions of CT are different (from the crystal structure) for each insulin/IRDb complex because TAMD trajectories were started based upon
the MC-docked and MD-equilibrated structural models of each insulin/IRDb complex (see Supporting Information results for the position of CT
during 11-ns MD-equilibration of each complex). Some of the terminal residues of CT spontaneously fold/unfold during TAMD trajectories.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
H. Vashisth and C.F. Abrams
1020 PROTEINS
(iv) the C-terminus of the B-chain of each insulin moves
through a narrow cleft between the L1 and CR domain
to the top of L1, where it stably fluctuates for the last 10
ns of each TAMD trajectory. The dynamics of receptor
during TAMD simulations is described in Supporting In-
formation Results.
Thermodynamics of conformational change
in each insulin via string method
The fact that TAMD51–53 allows exploration of the
physical free-energy surface for conformational sampling
implies that conformations observed under TAMD are
statistically significant,65,66 suggesting insulin molecules
can undergo structural changes (in the C-terminus of the
B-chain) that result in exposure of their hydrophobic
core for recognition by IR. However, for a detailed ther-
modynamic characterization of the transition mechanism,
we used the string method in CVs54,67–71 to refine the
pathway generated by TAMD for each insulin toward the
minimum free-energy path (MFEP). String method is a
technique to compute MFEP in a large but finite set of
CVs by iteratively refining an initial ‘‘string’’, that is, a
collection of discrete configurations of the system
referred to as images (see Supporting Information Meth-
ods). Free-energy profiles for the converged pathways
appear in Figure 3(A). The profile for T-insulin [black
trace; Fig. 3(A)] suggests a significantly high 37 
4.5 kcal/mol free-energy barrier (at image 6) for the tran-
sition in the C-terminus of the B-chain of bound-insulin
before a metastable intermediate state is observed (at
image 8) with DF  12.67  9 kcal/mol (with reference
to image 0). The C-terminus of the B-chain in this meta-
stable region, although away from the N-terminal resi-
dues of the A-chain, is still located in a narrow cleft
between the L1 and CR domains of IR [Fig. 3(B)]. No
other metastable intermediate states are observed for T-
insulin, and a positive DF (with reference to image 0) for
all images suggests that it is thermodynamically unfavor-
able for T-insulin to undergo conformational change in
the C-terminus of its B-chain with CT peptide present in
its nearly crystallographic position as seen in the crystal
structure (PDB code 3LOH).
However, we observe a significantly different trend in
the free-energy profile for R-insulin [cyan trace; Fig.
3(A)]. Notably observed are metastable states at images
2, 5, 9, and 15–18, and transition states at images 3, 6,
and 11. Thermodynamic preference for conformational
change observed in aforementioned images is indicated
by a negative DF (with reference to image 0) for each of
these images. A key structural feature in images from 1
to 9 is the separation of the C-terminus of the B-chain
[which is positioned between L1 and CR; Fig. 3(B)] that
exposes 50% of BSA (see Supporting Information
Results) between the C-terminus of the B-chain (B21–
B30) and rest of R-insulin. The relative free-energy differ-
ence between images from 1 to 9 is 2–4 kcal/mol,
suggesting a dynamic equilibrium among these confor-
mations where insulin partially exposes its hidden hydro-
phobic core. Other than placement of the C-terminus of
the B-chain of insulin in the proximity of the top rungs
of L1, an important distinguishing feature of the transi-
Figure 3
Thermodynamics of conformational change in the C-terminus of the
B-chain of each insulin. (A) Converged free-energy profiles along the
minimum free energy path (MFEP) computed via string method are
shown for each insulin. (B) Representative snapshots of MFEP images
are shown: T-insulin (0, 6, and 8); and R-insulin (0, 2, 6, 9, 11, and
18). The larger/smaller panels are higher/lower in free-energy,
respectively, and the arrows indicate the same. Compare Figure 2 for
coloring and labeling scheme. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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tion state at image 11 is the onset of rotation of insulin
molecule (vide infra) such that the N-terminal residues
of the A-chain directly contact L1, and BSA between R-
insulin and L1 significantly increases, consistent with
rearrangements spontaneously occurring in TAMD simu-
lation of R-insulin. However, we note that before crossing
transition state at image 11, there is a relatively high
free-energy barrier of at least 15 kcal/mol for confor-
mational change in the C-terminus of the B-chain of R-
insulin. Also, further separation of the C-terminus of the
B-chain of R-insulin beyond placement on the top of L1
is thermodynamically unfavorable, as indicated by an
increase in free-energy at images 19 to 24. The BSA
between R-insulin and L1 at initial image 0 and the lowest
free-energy image 18 are 270 A˚2 and 820 A˚2, respec-
tively. The free-energy difference (DF) between image 0
and 18 is 239.71 kcal/mol. The CT peptide remains asso-
ciated with L1 in all MFEP images, and has a BSA with
L1 of 1120 A˚2 at lowest-free energy image 18.
Highlighted in Figure 4 are the positions of the A- and
B-chain of R-insulin on the L1 surface along with CT for
MFEP images 0 (red), 12, 18, and 24 (blue). We observe
that after reaching the transition state at image 11, the
entire R-insulin molecule experiences an anticlockwise
rotation (looking at the L1 surface) and also translates
toward the top of L1 with its B-chain helix nearly parallel
to CT, which places the N-terminal residues of the A-
chain (GlyA1, IleA2, and ValA3) in the vicinity of Asp12
and Gln34 (L1). After rotation/translation of R-insulin,
the side-chain of Tyr708 (located near Leu36, Leu37, and
Phe64 of L1) is the only CT residue closest (10 A˚) to
the A-chain ValA3 as highlighted in Figure 4.
Insulin recognition in a displaced-CT IR
The structural models described above suggest that
both T and R-insulin can be docked in one out of two
binding pockets of IRDb with no major displacement of
the CT-peptide. Furthermore, it is thermodynamically
unfavorable for T-insulin to undergo conformational
change in its flexible C-terminus of the B-chain (B21–
B30), while the same conformational change in receptor-
bound R-insulin is favorable but the underlying free-
energy barriers (required for R-insulin to achieve a
tighter registry with L1) are relatively high. Because no
contacts between the C-terminal residues of the B-chain
(B21–B30) of either insulin and the CT-peptide are
observed even after this conformational change, it
remains unclear from these structural models how
photo-probes in the N-terminal residues of the A-chain
of insulin and also in the C-terminal residues of the B-
Figure 4
Orientation of the A-chain of R-insulin. (A) Representative snapshots of R-
insulin, CT, and the L1 domain from MFEP images 0 (red), 12, 18, and 24
(blue) are shown and labeled. Varying orientation of the A-chain of R-
insulin can be traced via the highlighted side-chain of VA3, which is shown
in sticks and labeled for image 0 with image index indicating further posi-
tions. Shown in sticks and labeled is also the side-chain of Y708 (CT).
Highlighted also are the positions of the C-terminus of the B-chain of in-
sulin (labeled C in red for image 0) along with the stick representations of
FB24, FB25, and YB26. The black arrow indicates viewing direction for panel
(B), where similar structural features as in panel (A) are shown except the
C-terminus of the B-chain of insulin, which is omitted for clarity. Change
in the orientation of the B-chain of insulin and CT are apparent in this
view due to conformational change in the insulin-tail (B21–B30). [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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chain can crosslink to the CT peptide simultaneously.39,72
These structurally unexplained observations along with the
following additional experimental evidence suggest that the
CT peptide is potentially mobile and may be displaced from
its crystallographic position by the incoming insulin mole-
cule10: (a) site-1 insulin mimetic peptides can compete
with CT for binding to the L1 domain of IR,50 (b) tighter
binding of aromatic-substituted CT peptides to apo-IR leads
to a commensurate loss of insulin affinity,39 and (c) the
photo-probes in the b-strands 2 and 3 of L1 can efficiently
crosslink to insulin despite the fact that they are shielded by
CT in the crystal structure (PDB code 3LOH).73 Interest-
ingly, there is a close structural relationship between the B-
chain of R-insulin (B1–B18) and the resolved structure of
the CT peptide (693–710): both are 18-residue-long a-heli-
ces. Hence, it has been speculated that the B-chain helix of
insulin can potentially displace CT peptide.10 We therefore
conjectured that preopened R-insulin (Supporting Informa-
tion Fig. S15) could dock if CT is displaced. With the above
observations in mind, we constructed a second physically
plausible structural model of the R-insulin/IRDb complex
based upon the structural models described above. In this
new model, the B-chain helix of R-insulin is presumed to
have displaced the CT peptide from its original position,
which we mimic by swapping the positions of R-insulin
and CT in the lowest free-energy image 18 of the non-CT-
displaced minimum free energy path (Fig. 3) based upon
the structural alignment of their respective a-helices. This
provides a basis for an initial placement of CT different
from that in the 3LOH structure and onto which we can
repeat MC docking of R-state insulin. We launched MC
dockings of the swapped insulin/CT configurations by car-
rying out independent exhaustive conformational sam-
pling of preopened R-insulin (Supporting Information
Fig. S15) and receptor conformations from MD trajecto-
ries (see Supporting Information Methods for details). We
Figure 5
Displaced-CT model of insulin binding. (A) Overlay of R-insulin and the CT peptide on the surface of the L1 domain is shown from a typical
docking with CT displaced from its original position by the B-chain helix (B1–B19) of insulin. Individual chains of insulin, CT, and L1 are colored
and labeled. The flexible C-terminus of the B-chain of insulin is highlighted in yellow along with the sidechains of key residues where PheB24 and
TyrB26 are known to crosslink to L1, while PheB25 and ThrB27 are known to crosslink to CT. Colored and highlighted in spheres are the
sidechains of the N-terminal residues of the A-chain of insulin IleA2, ValA3, and GluA4 that are known to crosslink to CT. Also shown in sticks are
the sidechains of Lys694, Phe701, and Phe705 of CT as reference. Key ligand-binding residues on L1 are also shown as a cyan transparent surface.
Other domains of the receptor are omitted for clarity. (B) Ensemble of 10 MC-docked configurations of R-insulin and CT on the surface of the L1
domain is shown.
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find that both R-insulin and CT can be docked relatively
easily without any structural overlap with receptor
domains in this displaced-CT model.
We show the overlay of R-insulin and CT on the surface
of the L1 domain of IR from a typical docked configuration
in Figure 5(A), and the conformational variability of R-insu-
lin and CT is depicted by 10 MC-docked configurations
shown in Figure 5(B). Looking at the L1 surface [Fig. 5(A)],
CT has now been displaced to the right of insulin in com-
parison to its original crystal structure position which is
approximately occupied by the B-chain helix of R-insulin.
Furthermore, both ligand and CT are still located in prox-
imity to the ligand-binding patch on L1 [transparent cyan
surface in Fig. 5(A)] where they can achieve specific registry
with L1. Most importantly, this model helps rationalize
photo-crosslinking experiments72 which suggest that the N-
terminal residues of the A-chain of insulin (IleA2, ValA3,
and GluA3) directly crosslink to CT, which is possible in
our newer model given their proximity to the N-terminus
of CT [Fig. 5(A)]. The bifunctional derivatives of photo-
probes have further indicated that PheB24 and PheB26
crosslink to L1, while surprisingly, probes at residues
PheB25 and ThrB27 crosslink to CT.39 This is possible in
the displaced-CT model as the sidechains of B24/B26 are
oriented toward L1, and of B25/B27 are oriented toward the
C-terminal end of resolved CT. We note that such place-
ment of the flexible C-terminus of the B-chain of insulin
(yellow cartoon in Fig. 5) has been possible due to a sponta-
neous separation of the C-terminus of the B-chain of ligand
from the rest of R-insulin in a longer unbiased MD simula-
tion (Supporting Information Fig. S15). As mentioned
above, it is interesting to point out that the conformations
of R-insulin, where the C-terminus of the B-chain is
detached from rest of the insulin molecule, fail to dock in
the receptor with CT in nearly crystallographic position.
The orientation of R-insulin in this displaced-CT model also
places the site-2 surface of ligand in the proximity of the
(F1–F2)0 loops where site-2 residues on receptor are located
(Supporting Information Fig. S16). Equilibration of this R-
insulin/IRDb complex is described in Supporting Informa-
tion Results and Supporting Information Fig. S17.
The facts that it was relatively easy to dock R-insulin/CT
in the swapped states, and the entire complex remains intact
during MD-equilibration, suggest that the B-chain helix of
R-insulin can potentially displace CT from its crystallo-
graphic position. However, it is not yet clear if such place-
ment is also thermodynamically favorable, which we further
tested. To understand the relative free-energy differences
between microscopically distinct MC-docked conformations
in the displaced-CT model, we further carried out string
method calculations (see Supporting Information Methods)
by evolving toward MFEP an initial string comprised of 10
MC-docked configurations. Because docked R-insulin had
already undergone conformational change in the C-terminus
of its B-chain, as collective variables to compute the free-
energy profiles via the string method, we used the center-of-
mass coordinates of R-insulin and CT to allow their better
placement on the L1 surface. We show the free-energy pro-
file from the converged string as well as from each string-
Figure 6
Thermodynamics of MC-docked configurations of the displaced-CT
model. (A) Converged free-energy profile (red trace) along the
minimum free energy path (MFEP) computed via string method is
shown for the R/IRDb complexes in the displaced-CT model. Inset
shows the free-energy profiles at each string iteration (blue; first itera-
tion, and red; last iteration). (B) Overlay of R-insulin and CT on the
surface of the L1 domain of IR is shown for metastable MFEP images 3
(dark color cartoons) and 6 (light color cartoons). Arrows depict the
clockwise rotation of CT during transition from image 3 to image 6.
Compare Figure 5 for coloring and labeling scheme. [Color figure can
be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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iteration in Figure 6(A). The converged free-energy profile
[red trace in Fig. 6(A)] shows that the majority of MC-
docked configurations have a negative DF (with reference to
image 0), suggesting that it is thermodynamically favorable
to place R-insulin and CT in swapped configurations. The
free-energy profile further reveals two metastable intermedi-
ates among 10 MC-docked models, which belong to images
3 and image 6 with DF  26.33  1.40 kcal/mol and 27.95
 0.82 kcal/mol, respectively. A small free-energy barrier of
1.5 kcal/mol (image 4; transition state) is observed
between images 3 and 6. We observe two key structural dif-
ferences in R-insulin/CT configurations at images 3 and 6
[Fig. 6(B)]: both R-insulin and CT rotate clockwise from
image 3 to image 6, resulting in lowering of the free energy
and better positioning of R-insulin/CT on the L1 surface.
These data jointly suggest that the displacement of CT by
the R-insulin is thermodynamically favorable, and the
underlying free-energy barriers for the adjustment of R-insu-
lin and CT on the L1 surface are relatively low.
DISCUSSION
In this work, we have endeavored to understand the
conformational reorganization of insulin on binding to
its receptor in the presence of a recently resolved39 criti-
cal tandem hormone-binding element, the CT-peptide.
Our previously successful MD-assisted MC docking algo-
rithm46,47,57 demonstrates that both T- and R-insulin
can be accommodated along with the crystallographically
positioned CT peptide in one out of two binding pockets
of IRDb without any major displacement of CT. Specifi-
cally, the contacts of TyrB16 with Phe39 (L1) for each in-
sulin are consistent with previous models45,46 and photo
crosslinking studies.74 A key B-chain residue of insulin is
ValB12, that has been suggested to contact L1,74 as
observed here: ValB12 contacts Leu36 and Asp12 (L1) in
T/IRDb complex, and Leu36 and Gln34 (L1) in R/IRDb
complex. The side-chain of GluB13, the mutations of
which disrupt insulin binding to IR,17,75 salt-bridges to
either Arg14 (L1) in T/IRDb or Lys703 (CT) in R/IRDb.
Both models suggest a GluB13 site-1 contact with IR, as
opposed to site-2 contact with IR.4,5 The side-chain of
HisB10 partially interacts with Lys703 and Thr704 (CT) in
T/IRDb, and does not contact any IR residue in R/IRDb,
leaving open the possibility of it being a site-2 contact
with IR.4,5 The cluster of site-2 residues of each insulin
(Supporting Information Table S1) SerA12, LeuA13, TyrA14,
GluA17, LeuB17, and ValB18 interacts (see Results) with
suggested33 site-2 residues in the fibronectin loops of IR
(Asp483, Lys484, Leu552, Arg554, Lys557, and Leu558). The
observation that each insulin can contact site-1 residues
in the L1 domain of one subunit and site-2 residues in
the fibronectin domain (F1) of the other subunit of IR is
of particular significance, because it suggests crosslinking
of receptor subunits by insulin which was demonstrated
earlier.76
Furthermore, our characterization of the conforma-
tional change in the C-terminus of the B-chain of T- and
R-insulin via TAMD simulations and the string method
suggests that: (i) each insulin molecule can undergo con-
formational change in the C-terminus of the B-chain
(B21–B30), but such opening of the C-terminus of the
B-chain in receptor-bound ligands is thermodynamically
favorable only for R-insulin albeit involving high free-
energy barriers; (ii) this conformational change exposes
the hydrophobic core of each insulin, but the exposed
surface of only R-insulin achieves significantly increased
registry with the L1 domain due to the rotation/transla-
tion of R-insulin molecule (Fig. 4). Registry with L1 for
T-insulin is largely prevented due to steric hindrance
posed by the unfolded conformation of the N-terminus
of the B-chain (B1–B8); (iii) the side-chain of ThrA8
does not directly contact any IR residue, consistent with
suggestions that hormone–receptor interface is not tightly
packed at this site because diverse A8 substitutions are
easily tolerated.77
These structural models where CT is not significantly
displaced from its crystallographic position, however, fail
to explain some key photo-crosslinking and mutational
experiments21,30,39,72,73,78 as well as the observations
from helical insulin mimetic peptides50,55,56, which sug-
gest that CT is potentially mobile and needs to be dis-
placed by insulin10 for it to achieve specificity with the
L1 domain of IR. Considering these aspects, we con-
structed a second R-insulin/IRDb structural model based
upon the observation that the positions of the B-chain
helix of only R-insulin (B1–B18) and a-helical CT (693–
710) can be easily swapped without any structural over-
lap with any receptor domain, and also that R-insulin
can spontaneously undergo conformational change in its
C-terminus of the B-chain (B21–B20) on a longer MD
equilibration (Supporting Information Fig. S15). The dis-
placed-CT model suggests that it is now possible for
photo-probes in the N-terminal residues of the A-chain
of insulin to crosslink to residues in the N-terminus of
CT, while probes in the C-terminus of the B-chain at
B24/B26 can crosslink to L1 and B25/B27 can crosslink
to CT, as suggested before.29,39,72 The most direct ex-
perimental evidence in favor of the displacement of CT
by insulin (as suggested by our model) comes from
recent photo-crosslinking experiments of Whittaker
et al.73 (See, however, the Note in Proof.) These experi-
ments showed that the side-chains of L1 residues Leu36,
Leu37, Leu62, and Phe64, normally buried in the aCT/
L1 interface of IRDb,39 can efficiently and predomi-
nantly crosslink to the B-chain of insulin, which means
that CT needs to be displaced for insulin to contact these
side-chains. Also, the orientation of R-insulin in our
model is consistent with ligand crosslinking of receptor
subunits76 because the ligand can maintain simultaneous
contact at site-1 with L1 and at site-2 with the (F1–F2)0
loops. These observations are also in accord with a pro-
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posed sequential model of association of insulin-binding
sites 1 and 2 to IR.79 As a next step, this new structural
model also helps explain recognition of IR by homolo-
gous (to insulin) noncognate ligands such as a single-
chain polypeptide insulin-like growth factor-1 (IGF1),
which cannot undergo significant separation of its C-do-
main due to single-chain structural constraints. Specifi-
cally, we show in Supporting Information Fig. S18 an
overlay of IGF1 along with insulin and CT on the surface
of the L1 domain of IR, where IGF1 A/B-domains are in
the same orientation as insulin, and the FYF (23–25)
sequence in the C-domain of IGF1 can substitute for the
critical FFY (B24–B26) sequence of insulin (see high-
lighted sidechains of these residues in Supporting Infor-
mation Fig. S18). We speculate that the position of CT as
observed in the crystal structure of apo-IRDb (PDB code
3LOH), where CT shields insulin-binding patch on L1
can be a mechanism to protect the ligand-binding surface
of the receptor, which can only be exposed by specific
binding of insulin or its mimetic via displacement of CT.
An outstanding question in understanding insulin rec-
ognition by IR has been the unknown receptor-bound
state of hormone, because classical crystallographic con-
formers of hormone (T and R; the difference is that B1–
B8 residues are in an extended conformation in T, while
same residues are helical in R) have the receptor-binding
surface hidden in their interior.40 The R-state, however,
has been suggested to be less stable, but more active (in
comparison to more stable, but less active T) form of
hormone that binds to IR.9,45,62,80 Furthermore, exten-
sive experimental investigations of insulin structure40–
44,63,64,72,77,81–95 have proposed a ‘‘detachment
model’’, which posits that the C-terminus of the B-chain
(B21–B30) of insulin detaches itself (from rest of the in-
sulin molecule) via an ‘‘induced-fit’’ mechanism such
that the residues in the N-terminus of its A-chain are
exposed. The proposed induced-fit in the C-terminus of
the B-chain (B21–B30) also lends support to photo-
crosslinking studies suggesting that probes at A1–A4, A8,
A14, B25, and B27 crosslink to the same CT-peptide,
while probes at B16, B24, and B26 crosslink to the L1
domain.29,39,63,72,74,78 Using TAMD simulations and
string method calculations, we find that the receptor-
bound T-insulin cannot undergo this conformational
change via a thermodynamically favorable path, while the
receptor-bound R-insulin can undergo this change to a
certain extent beyond which it needs to overcome rela-
tively high free-energy barriers. Interestingly, we also
observe via unbiased simulations that free wild-type R-
insulin can spontaneously separate the C-terminus of its
B-chain (Supporting Information Fig. S15) to expose the
residues in the N-terminus of the A-chain. Given that we
can readily dock this exposed conformation of R-insulin
along with CT in our displaced-CT model suggests that
the opening of the B-chain C-terminus alone may not be
the basis of the induced fit, but that insulin recognition
by IR may be merely a ligand conformational-selection
phenomenon. However, it is not unlikely that further
conformational changes in R-insulin on binding to recep-
tor might be required to achieve high-affinity recogni-
tion. Observation of a spontaneous conformational
change in R-insulin and a thermodynamically favorable
displacement of CT by the B-chain helix of R-insulin
(B1–B19) in our displaced-CT model suggest that R-insu-
lin may be the receptor-bound form of hormone, in
accord with earlier experiments.
Finally, we speculate on the implications of this work
on the negative-cooperativity of high-affinity insulin-IR
binding.16,48,96 The CT-peptide lies at the C-terminus
of the so-called insert domain (ID), an excursion from
the second folded type-III fibronectin (F2) domain. At
least one disulfide bridge in the Cys-triplet (682, 683,
and 685) links the two IDs97, presumably beneath the
apex of the folded-over arch of the dimeric receptor. If
one CT is displaced as we suggest here, the connectivity
to the other CT through the ID disulfide might hinder
the displacement of the CT of the other monomer, mak-
ing it much more difficult to realize a high-affinity
bound state on both sides of the receptor. Consistent
with these ideas, we point out that many receptor con-
structs have indeed been experimentally studied that sug-
gest the role of one or more intersubunit disulfides in
high-affinity insulin binding and negative cooperativity.
Particularly, the dimeric receptor constructs that contain
either a disulfide at Cys524 or a disulfide at the Cys-
triplet alone fail to show high-affinity binding and nega-
tive cooperativity.3,97,98 Interestingly, however, both
high-affinity binding and negative cooperativity could be
restored in dimeric receptor constructs where disulfides
at Cys524 and at least one of Cys682/Cys683/Cys685 are
simultaneously present.26 Therefore, it appears that the
role of at least one disulfide at Cys-triplet (682, 683, and
685) is to provide a structural constraint that can allow
high-affinity insulin binding only in one out of two
ligand-binding pockets of IR. Based upon our distance
measures between the membrane-proximal domains of
IR in apo and ligand-bound simulations (see Supporting
Information Discussion, and Supporting Information Ta-
ble S2), we speculate that constraints on receptor legs via
membrane anchors may further help insulin in achieving
high-affinity and specificity for IR.99–101
Limitations of all-atom structural models
We note that structural models presented here are bi-
ased toward the crystallographic conformation of
IRDb,7,39 which has missing residues (IDa, 656–719;
IDb 724–754). We point out that the orientation of R-in-
sulin and CT on the L1 surface in the displaced-CT
model represents a metastable state and further rear-
rangements in insulin/CT may still occur for both to
achieve specificity with L1. (See again the Note in Proof.)
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The exact position of CT on L1 is likely also governed by
the structural constraints posed by the missing linkers.
Therefore, we point out that the novel physically-plausi-
ble placement of CT in our displaced-CT model remains
a testable prediction for future experiments. We also
point out that several experimental studies have previ-
ously estimated binding affinity of insulin for various re-
ceptor constructs.26,27,31,32,100,101 Although the
potential of mean force (PMF) calculation should be able
to provide an estimate of binding affinity of insulin in
principle, we have expressly chosen not to make compar-
isons to known experimental estimates of binding affinity
for the following reasons: (1) The first PMFs that we
have computed (Fig. 3) here are for the conformational
reorganization of insulin on receptor binding. Specifi-
cally, the free-energy difference is associated with the
conformational change in the C-terminus of the B-chain
of insulin, which possibly contributes to an unknown
extent to the binding-affinity of insulin. The second PMF
calculation (Fig. 6) provides free-energy differences
between different MC-generated states of preopened
insulin/CT. Therefore, these free-energy differences are
related to both the placement of preopened insulin as
well as the displacement of CT, and are likely not separa-
ble into individual contributions; and (2) The receptor
structure we have used here to construct our structural
models has missing structural elements in the insert
domains, both downstream and upstream of CT. We have
not attempted to model these large unstructured missing
portions of IR without any experimental data to guide
their placement. These missing structural elements may
also contribute to binding affinity, and hence a direct and
fair comparison may not be feasible at this point. How-
ever, if one were to assume that there is no net free-energy
change associated with the movement of CT on the L1
surface, the free-energy change (DF) we have reported for
our displaced-CT model is 27.0 to 28.0 kcal/mol,
which corresponds to a sub-nanomolar (nM) affinity for
insulin in our structural models. This is in qualitative
agreement with known nanomolar (nM) affinity of insulin
for soluble receptors in the presence of CT. Also, we have
not explored the role of membrane-anchors, and neither
have we attempted to understand the role of glycosylation,
which remain ambitious goals for future studies.
CONCLUSIONS
In this work, we have attempted to understand the
interplay of conformational changes involved in binding
of insulin to IR in the presence of a potentially flexible
tandem hormone-binding element, the CT peptide. With
the help of MC docking, MD simulations, TAMD simu-
lations, and the free-energy calculations via string
method, we propose potential modes of insulin recogni-
tion by IR, which are consistent with a plethora of exper-
imental evidence, and help rationalize some yet unex-
plained photo-crosslinking studies. Our models support
the experimental view that the B-chain helix of R-insulin
(B1–B19) can potentially displace flexible CT for insulin
to achieve specificity with the L1 domain of IR. We also
offer details that suggest R-insulin as a candidate for spe-
cific recognition by IR as previously suggested by others
based on various experiments.9,45,62,80
NOTE ADDED IN PROOF
A crystallographic structure of insulin bound to CT-
containing minimal receptor constructs appeared in print
after acceptance of our article [Menting et al., Nature
2013 493:241–245]. We briefly mention that, although
the detailed registry of residue contacts between insulin
and IR in our model do not match this new structure,
displacement of CT from its position in the 3LOH struc-
ture is confirmed. We also point out that the minimal re-
ceptor constructs lack many receptor domains, and when
aligned into a full ectodomain structure, the new insulin-
bound structure suffers many severe steric clashes with
these domains. We are currently working to resolve the
disagreement and clashes using our docking methods and
will report on them in a future publication.
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